文献速递湿疹皮炎与荨麻疹

单剂度普利尤单抗治疗6月龄至<6岁重症特应性皮炎的2期开放标签研究:药代动力学、安全性与疗效

A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-11-08

结果显示单剂度普利尤单抗总体耐受良好,显著降低EASI和峰值瘙痒NRS评分,药代动力学呈非线性,安全性与成人、青少年和儿童相似。

要点

  • 单剂度普利尤单抗在6月龄至<6岁重症AD患儿中总体耐受良好。
  • 第3周EASI和峰值瘙痒NRS较基线显著下降,但第4周多数疗效指标改善减弱。
  • 药代动力学呈非线性,暴露随剂量增加呈超比例增加。

核心结论

  • 单剂度普利尤单抗在6月龄至<6岁重症AD患儿中总体耐受良好,并大幅减轻AD的临床体征/症状。
  • 较大年龄儿童(≥2至<6岁)的疗效应答略优于较小年龄儿童(≥6月龄至<2岁)。
  • 度普利尤单抗的药代动力学呈非线性,与既往在成人和青少年中的研究一致。

研究设计与样本

  • 开放标签、多中心、2期、序贯、双年龄队列、双剂量水平研究(LIBERTY AD PRE-SCHOOL;NCT03346434)。
  • 纳入初始队列为≥2至<6岁较大儿童,随后纳入≥6月龄至<2岁较小儿童。
  • 单次皮下注射度普利尤单抗,序贯两个剂量组(先3 mg/kg,后6 mg/kg),允许使用标准化的低至中等效力外用糖皮质激素。
  • 在单次注射后4周内进行药代动力学采样、安全性监测和疗效评估。

主要发现

  • 在每个年龄队列内,单次注射度普利尤单抗后的药代动力学暴露随剂量增加呈超比例增加。
  • 第3周,3 mg/kg和6 mg/kg度普利尤单抗使平均EASI评分分别降低:较大队列-44.6%和-49.7%,较小队列-42.7%和-38.8%。
  • 第3周,3 mg/kg和6 mg/kg度普利尤单抗使平均峰值瘙痒NRS评分分别降低:较大队列-22.9%和-44.7%,较小队列-11.1%和-18.2%。
  • 第4周,两个年龄组多数疗效结局的改善均减弱,尤其是较低剂量组。
  • 安全性特征与成人、青少年和儿童中观察到的相当。

临床怎么用

  • 单剂度普利尤单抗可为6月龄至<6岁重症AD患儿提供一种耐受良好的系统性治疗选择。
  • 治疗应答可能存在年龄差异,较大儿童应答略优,需关注较小年龄患儿的疗效评估。
  • 药代动力学呈非线性,剂量选择需考虑暴露的超比例增加。

局限性

  • 缺乏安慰剂对照,疗效解释需谨慎。
  • 长期安全性和多次给药疗效未在本研究中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dupilumab has demonstrated efficacy and acceptable safety in adults and children (aged 6-17 years) with moderate-to-severe atopic dermatitis (AD), but effective systemic therapy with a favorable risk-benefit profile in younger children remains a significant unmet need. OBJECTIVES: To determine the pharmacokinetics, safety and efficacy of single-dose dupilumab in children with severe AD aged ≥6 months to <6 years. METHODS: This open-label, multicenter, phase 2, sequential, two-age cohort, two-dose level study (LIBERTY AD PRE-SCHOOL; NCT03346434) included an initial cohort of older children aged ≥2 to <6 years, followed by a younger cohort aged ≥6 months to <2 years. Pharmacokinetic sampling, safety monitoring and efficacy assessments were performed during the 4-week period after a single subcutaneous injection of dupilumab, in two sequential dosing groups (3 mg/kg, then 6 mg/kg). The use of standardized, low-to-medium potency topical corticosteroids was allowed. RESULTS: Forty patients were enrolled (20/age cohort, 10/dose level within a cohort) between December 20, 2017 and July 22, 2019. Within each age cohort, pharmacokinetic exposures after a single injection of dupilumab increased in a greater than dose-proportional manner. At week 3, treatment with 3 and 6 mg/kg dupilumab reduced scores of mean Eczema Area and Severity Index by -44.6% and -49.7% (older cohort) and -42.7% and -38.8% (younger cohort), and mean Peak Pruritus NRS scores by -22.9% and -44.7% (older cohort) and -11.1% and -18.2% (younger cohort), respectively. At week 4, improvements in most efficacy outcomes diminished in both age groups, particularly with the lower dose. The safety profile was comparable to that seen in adults, adolescents and children. CONCLUSIONS: Single-dose dupilumab was generally well tolerated and substantially reduced clinical signs/symptoms of AD. Slightly better responses were seen in older than younger children. The pharmacokinetics of dupilumab were non-linear, consistent with previous studies in adults and adolescents.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Paller AS, Siegfried EC, Simpson EL, et al. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2020. PMID: 32893393. doi:10.1111/jdv.16928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。